CSL's Global Role in Battling COVID-19

  • CSL Behring is part of an unprecedented industry alliance to develop a potential plasma-derived therapy for treating COVID-19. The alliance will work toward developing one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals at high risk of COVID-19, and to support national governments in their efforts to fight the current pandemic. The collaboration will leverage leading-edge expertise and work that the companies already have underway. Click here f
  • /Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.